Singapore-based microRNA diagnostics firm MiRxes said Thursday that it has launched an initial public offering on the Hong Kong Stock Exchange, selling 46,620,000 Hong Kong offer shares and 41,958,000 international offer shares at HK$23.30 (US$2.98) per share for approximately HK$880.5 million (US$112.8 million) in net proceeds.

Dutch diagnostics firm MRC Holland said Thursday that its liquid biopsy test for Peutz-Jeghers syndrome has been certified under Europe's In Vitro Diagnostic Regulation (IVDR).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform.

Real-world data firm Cota said Thursday that it has teamed up with Guardant Health to provide biopharmaceutical researchers access to a combined database that will include its own electronic health record data and Guardant’s genomic testing results from cancer patients.

PreAnalytiX GmbH, a joint venture between QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) and BD (Becton, Dickinson and Company; NYSE: BDX), today announced the launch of the PAXgene® Urine Liquid Biopsy Set, which enables the reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS). The new set will be commercialized by QIAGEN.

Sysmex Inostics said Tuesday that it has secured New York State Department of Health approval for clinical trial use of the firm's liquid biopsy assay for biomarkers that are relevant for the treatment of multiple cancer types.

Pillar Biosciences, Inc., has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing, using rapid, Next Generation Sequencing (NGS)-based liquid biopsy tumor profiling panels for detection of genetic cancer variants, with an initial focus on European markets and the UK.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS (“Policlinico Gemelli”) to establish an in-house liquid biopsy testing service as a part of its diagnostics services within its hospital system. Leveraging Guardant Health’s cutting-edge proprietary digital sequencing platform, this initiative will include on-site analysis of Guardant360 ® CDx liquid biopsy tests directly within the Policlinico Gemelli facilities in Rome, Italy.

The US Attorney's Office for the Northern District of California said earlier this week that cancer testing company Guardant Health has agreed to settle allegations that it knowingly violated the False Claims Act and regulations of the Defense Health Agency.

Roche subsidiary Foundation Medicine said Monday that the US Food and Drug Administration has approved its liquid biopsy test, FoundationOne Liquid CDx, as a companion diagnostic to identify advanced BRCA-mutated prostate cancer patients who are eligible for treatment with Janssen's Akeega (niraparib and abiraterone acetate).